Physician profile
Eric K Davis
NPI 1932277498
$8,748.60
in general payments reported to CMS, 2019-2025
51 companies · $1,114 in 2025
The $1,114 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $484 · 2020: $829 · 2021: $2,006 · 2022: $1,331 · 2023: $1,464 · 2024: $1,520 · 2025: $1,114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,027 · Education: $57.74 · Entertainment: $13.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,027.09 |
| Education | $57.74 |
| Entertainment | $13.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,285.51 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Otsuka America Pharmaceutical, INC. | $480.04 | 2021-2025 | Rexulti |
| Novo Nordisk INC | $463.45 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Allergan, INC. | $372.70 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $361.18 | 2020-2025 | Breztri, Farxiga |
| Janssen Pharmaceuticals, INC | $355.61 | 2019-2025 | Spravato |
| Lilly USA, LLC | $347.39 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Grifols USA, LLC | $339.35 | 2019-2025 | Prolastin-C Liquid |
| Glaxosmithkline, LLC. | $296.40 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Amarin Pharma, INC. | $243.80 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $229.47 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $225.05 | 2022-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.33 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Lundbeck LLC | $194.59 | 2022-2025 | Rexulti |
| Astellas Pharma US INC | $175.20 | 2019-2023 | Veozah |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.